16200-53-6Relevant articles and documents
Discovery of adamantane based highly potent HDAC inhibitors
Gopalan, Balasubramanian,Ponpandian, Thanasekaran,Kachhadia, Virendra,Bharathimohan, Kuppusamy,Vignesh, Radhakrishnan,Sivasudar, Velaiah,Narayanan, Shridhar,Mandar, Bhonde,Praveen, Rajendran,Saranya, Nithyanandan,Rajagopal, Sriram,Rajagopal, Sridharan
, p. 2532 - 2537 (2013/06/27)
Herein, we report the development of highly potent HDAC inhibitors for the treatment of cancer. A series of adamantane and nor-adamantane based HDAC inhibitors were designed, synthesized and screened for the inhibitory activity of HDAC. A number of compounds exhibited GI50 of 10-100 nM in human HCT116, NCI-H460 and U251 cancer cells, in vitro. Compound 32 displays efficacy in human tumour animal xenograft model.
HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF FUNGAL INFECTIONS
-
, (2011/06/16)
Described are bridged compounds of the formula (I), their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The invention relates to compositions and methods to treat fungal infection. These compounds are selective HDAC inhibitors that act as inherent antifungal compounds or enhance the activity of other antifungal compounds such as azoles.